Stock A216400 INVITES BIOCORE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Invites Biocore Co., Ltd.

Equities

A216400

KR7216400002

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
9,440 KRW +5.47% Intraday chart for Invites Biocore Co., Ltd. +6.43% +1.51%
2023 CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion CI
2023 Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion
CI
Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion
CI
Invites Biocore Co., Ltd. completed the acquisition of 85% stake in PROCAGEN from Byun Seok-soo.
CI
Invites Biocore Co., Ltd. agreed to acquire 85% stake in PROCAGEN from Byun Seok-soo.
CI
BioCore Inc. Signs Agreement with Osprey Medical, Inc
CI
Invites Healthcare Co., Ltd. agreed to acquire a 20.03% stake in Biocore Co., Ltd. from Hongkong Dian Biotechnology Co., Limited for KRW 12 billion.
CI
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion.
CI
Kiwoom Securities Co., Ltd. acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion.
CI
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd., MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion.
CI
SBI Investment Korea Co., Ltd. through its SBI-Growth Ladder KONEX Vitalization Fund acquired 2.3% stake in Biocore Co., Ltd. from Kyungryul Lee for KRW 1.9 billion.
CI
Moon-Kyu Gong acquired 1.22% stake in Biocore Co., Ltd. from Jeong-Woo Lee for KRW 700 million.
CI
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion.
CI
Biocore Co., Ltd. completed the acquisition of Cytogenetic and Human Genome division of Seoul Clinical Laboratories.
CI
Biocore Co., Ltd. agreed to acquire Cytogenetic and Human Genome division of Seoul Clinical Laboratories for KRW 2.9 billion.
CI
Intelsius Announces Partnership with Biocore Co. Ltd. in South Korea
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A216400 Stock
  4. News Invites Biocore Co., Ltd.
  5. Highlights